CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2024		Dec. 31, 2023		Dec. 31, 2022
Cash flows from operating activities:
Net loss		$ (43,009)		$ (213,361)		$ (339,567)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation and amortization expense		1,331		2,509		1,187
Amortization of notes and securities discounts and debt issuance costs		0		0		30
Stock-based compensation		114,331		140,931		164,305
Change in fair value of warrants and amortization of warrants		50		86		(900)
Accretion, net of amortization		(2,524)		(4,014)		(1,503)
Accrued interest earned		(571)		0		0
Net realized (losses) gains on investment securities		(480)		(20)		267
Gain on debt extinguishment on note payable		0		0		(23,326)
Loss (gain) on investment		467		4,726		(9,217)
Impairment of goodwill and other intangible assets		0		15,945		0
Premium deficiency reserve		0		(7,239)		(93,517)
Changes in operating assets and liabilities:
Accrued retrospective premiums		(19,177)		(1,689)		14,536
Prepaid expenses		1,244		3,728		(3,415)
Other assets		2,852		8,859		(8,208)
Healthcare receivables		12,625		6,443		(22,565)
Unpaid claims		19,296		(294)		1,077
Accounts payable and accrued expenses		(2,620)		4,739		7,635
Accrued salaries and benefits		(1,971)		(2,901)		8,784
Other liabilities		606		6,404		(203)
Net cash provided by (used in) operating activities from continuing operations		82,450		(35,148)		(304,600)
Net cash (used in) provided by operating activities from discontinued operations		(47,605)		(109,514)		100,674
Net cash provided by (used in) operating activities		34,845		(144,662)		(203,926)
Cash flows from investing activities:
Purchases of short-term investments, available-for-sale, and held-to-maturity securities		(201,241)		(175,567)		(369,396)
Proceeds from sales of short-term investments and available-for-sale securities		83,673		60,436		13,348
Proceeds from maturities of short-term investments and available-for-sale securities		119,689		255,728		472,098
Acquisition of business, net of cash acquired		0		0		(16,200)
Purchases of property and equipment		(1,556)		(584)		(4,467)
Acquisition of Clover Therapeutics Series A preferred shares		0		0		(250)
Net cash provided by investing activities		565		140,013		95,133
Cash flows from financing activities:
Issuance of common stock, net of early exercise liability		709		34		1,400
Issuance of common stock under employee stock purchase plan, net of stock issuance costs		193		1,116		0
Treasury stock acquired		(16,491)		(6,220)		(6,362)
Repurchases of common stock		(1,772)		0		0
Net cash used in financing activities		(17,361)		(5,070)		(4,962)
Net increase (decrease) in cash and cash equivalents		18,049		(9,719)		(113,755)
Cash and cash equivalents, beginning of period		176,494	[1]	186,213	[1]	299,968
Cash and cash equivalents, end of period	[1]	194,543		176,494		186,213
Reconciliation of cash and cash equivalents and restricted cash
Cash and cash equivalents	[1]	194,543		122,863		103,791
Restricted cash	[1]	0		53,631		82,422
Total cash, cash equivalents and restricted cash	[1]	194,543		176,494		186,213
Supplemental disclosure of non-cash investing and financing activities
Activities from Seek Dissolution		0		0		735
Right-of-use assets obtained in exchange for lease liabilities		0		0		642
Recognition of equity method investments and preferred stock		0		0		8,644
Derecognition of non-controlling interest		0		0		3,903
Conversion of Clover Therapeutics convertible note to preferred stock		$ 0		$ 0		$ 250

[1] (1) Includes all applicable amounts for both continuing and discontinued operations.